论文部分内容阅读
目的评价急性生理学与慢性健康状况评分Ⅲ(APACHEⅢ)对COPD急性加重期并呼吸衰竭患者病性评估的价值。方法对77例慢性阻塞性病急性加重期(AECOPD)并发呼吸衰竭患者进步APACHEⅢ评分,所有指标均取确诊呼吸衰竭后最初24h内的最差值,比较存活组与死亡组患者之间的差异,对不同分值段的并发症、死亡率进行比较分析。结果77例患者APACHEⅢ评分范围在25~125分,平均(52·34±22·41)分,存活组53例评分(41·02±10·16)分,死亡组24例评分(77·21±21·93)分。二者差异有统计学意义(P<0·01),随着APACHE评分可用于AECOPD合并呼吸衰竭患者的病性评估,有利于指导治疗及预测预后。
Objective To evaluate the value of acute physiology and chronic health status score Ⅲ (APACHE Ⅲ) in the evaluation of the disease in patients with acute exacerbation of COPD and respiratory failure. Methods The APACHE Ⅲ scores of 77 patients with AECOPD complicated by respiratory failure were evaluated. All the indexes were taken as the worst values in the first 24 hours after diagnosis of respiratory failure. The differences between survivors and death patients were compared. Comparisons of complication and mortality of different score segments were made. Results The APACHE Ⅲ score of 77 patients ranged from 25 to 125 points (mean 52 · 34 ± 22 · 41), 53 cases (41 · 02 ± 10 · 16) in survivors and 24 cases in death group (77 · 21) ± 21 · 93) points. The difference was statistically significant (P <0.01). With the APACHE score can be used for the evaluation of the disease in patients with AECOPD complicated with respiratory failure, it is helpful to guide the treatment and predict the prognosis.